Therapy Areas: Vaccines
Study suggest AstraZeneca's second COVID-19 vaccine dose doesn't raise risk of rare blood clots
28 July 2021 -

A study led and funded by British pharmaceutical company AstraZeneca (LON:AZN) has revealed that the company's COVID-19 vaccine did not increase the instances of rare blood clots with low platelets in people after the second dose, Reuters news agency reported on Wednesday.

This study evaluated reported COVID-19 cases occurring within 14 days of administration of the first or second dose as of 30 April 2021, using the company's global safety database.

Data from the study published in the Lancet medical journal found that the estimated rate of thrombosis with thrombocytopenia syndrome (TTS) after the second dose of the vaccine was 2.3 per million in those inoculated, comparable to the typical rate seen in those who have not been vaccinated.

That rate was 8.1 after the first dose, the company added.

The EU drug regulator has been looking into cases of TTS since March 2021 and has found a possible link to Vaxzevria and to Johnson & Johnson's (NYSE:JNJ) single-dose shot. It has however maintained that the overall benefits of both the vaccines outweigh any risks posed by them.